Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens in Patients with Gastro-Oesophageal Adenocarcinoma By Ogkologos - March 26, 2025 965 0 Facebook Twitter Google+ Pinterest WhatsApp Biomarker analyses from the CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Fertility Preservation Safe for Young Women with Breast Cancer December 22, 2020 Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening... January 22, 2026 Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced... May 28, 2024 Load more HOT NEWS Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens... 2021/22 in review: Charity looks to the future with ambitious new... FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable Non-Small Cell Lung Cancer Teen With Terminal Cancer Gives Make-A-Wish Gift To Other Kids In...
